Supplemental material
Hematology
Volume 24, 2019 - Issue 1
Articles
Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia
, , , , 
, , , , , , , , , , & show all
Michael DoubekDepartment of Internal Medicine, Hematology and Oncology, University Hospital, Brno, Czech Republichttps://orcid.org/0000-0002-1269-6282View further author information
https://orcid.org/0000-0002-1269-6282View further author information, , , , , Elena ParovichnikovaNational Research Center for Hematology, Moscow, Russiahttps://orcid.org/0000-0001-6177-3566View further author information
https://orcid.org/0000-0001-6177-3566View further author information, , Josep-Maria RiberaICO-Hospital Germans Trias I Pujol, Josep Carreras Research Institute, Barcelona, Spainhttps://orcid.org/0000-0003-1042-6024View further author information
https://orcid.org/0000-0003-1042-6024View further author information, , , & show allRelated Research Data
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Source:
Massachusetts Medical Society
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
Source:
American Society of Hematology
International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia
Source:
Ferrata Storti Foundation (Haematologica)
Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia
Source:
American Society of Hematology
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study
Source:
American Society of Hematology
Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials
Source:
American Society of Hematology
Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually
Source:
Springer Nature
Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia
Source:
Taylor & Francis
Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Source:
Ferrata Storti Foundation (Haematologica)
Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol
Source:
Springer Nature
Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia
Source:
American Society of Hematology
Has MRD monitoring superseded other prognostic factors in adult ALL?
Source:
American Society of Hematology
Clinicians’ Perspectives on Cure in Adult Patients with Acute Lymphoblastic Leukemia with Minimal Residual Disease: A Delphi Study
Source:
Springer Science and Business Media LLC
Allografting in Primary Refractory ALL
Source:
Wiley
Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232
Source:
American Society of Hematology
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
Source:
Elsevier BV
Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies
Source:
American Society of Hematology
A Meta-analysis
Source:
American Medical Association (AMA)
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
Source:
Springer Nature
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
Source:
American Society of Hematology
Evaluation of Response-Time Data Involving Transient States: An Illustration Using Heart-Transplant Data
Source:
Informa UK Limited
Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL
Source:
Springer Nature
Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008
Source:
Springer Nature
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia
Source:
American Society of Hematology
Monitoring and Managing Minimal Residual Disease in Acute Lymphoblastic Leukemia
Source:
American Society of Clinical Oncology (ASCO)
Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia
Source:
Taylor & Francis
Linking provided by
